Tomoko Akaike

10PUBLICATIONS
35CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyPredictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 27, 2026
Minimal Efficacy of Single-Agent Anti-PD-(L)1 Re-Exposure in Anti-PD-(L)1-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients.

|Sep 19, 2025
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials.

Peter Y Ch'en, Yuzheng Zhang, Daniel S Hippe

|Aug 11, 2025
Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade.

Lisa Tachiki, Yasman Moshiri, Daniel S Hippe

|Mar 18, 2025
Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients.

Emily Gong, Lauren Zawacki, Xinyi Fan

|Jul 25, 2024
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy.

Tomoko Akaike, Austin J Jabbour, Peter H Goff

|Jul 25, 2024
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications.

Tomoko Akaike, Manisha Thakuria, Ann W Silk

Pageof 2

Frequent Collaborators

10 joint publications

Paul T Nghiem

6 joint publications

Shailender Bhatia

5 joint publications

Daniel S Hippe

5 joint publications

Song Youn Park